FT596 + Cyclophosphamide + Fludarabine + Rituximab + Obinutuzumab + Bendamustine
Phase 1Terminated 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma, B-Cell
Conditions
Lymphoma, B-Cell, Chronic Lymphocytic Leukemia
Trial Timeline
Mar 19, 2020 → Sep 27, 2023
NCT ID
NCT04245722About FT596 + Cyclophosphamide + Fludarabine + Rituximab + Obinutuzumab + Bendamustine
FT596 + Cyclophosphamide + Fludarabine + Rituximab + Obinutuzumab + Bendamustine is a phase 1 stage product being developed by Fate Therapeutics for Lymphoma, B-Cell. The current trial status is terminated. This product is registered under clinical trial identifier NCT04245722. Target conditions include Lymphoma, B-Cell, Chronic Lymphocytic Leukemia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04245722 | Phase 1 | Terminated |
Competing Products
20 competing products in Lymphoma, B-Cell